(Q41734634)

8 October 2017

1 reference

title

Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus (English)

1 reference

8 October 2017

M D Johnson

1

1 reference

8 October 2017

L K Campbell

series ordinal

2

1 reference

8 October 2017

R K Campbell

series ordinal

3

1 reference

8 October 2017

language of work or name

English

0 references

publication date

1 March 1998

1 reference

Annals of Pharmacotherapy

8 October 2017

published in

1 reference

8 October 2017

volume

32

1 reference

8 October 2017

issue

3

1 reference

8 October 2017

page(s)

337-348

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

8 October 2017

cites work

1 reference

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

Insulin resistance and the prevention of diabetes mellitus.

21 January 2018

1 reference

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

21 January 2018

1 reference

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

Impaired glucose tolerance in the U.S. population.

21 January 2018

1 reference

Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution.

21 January 2018

1 reference

Insulin insensitivity in offspring of parents with type 2 diabetes mellitus.

21 January 2018

1 reference

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

21 January 2018

1 reference

The prevalence of NIDDM and associated risk factors in native Canadians.

21 January 2018

1 reference

Circulating proinsulin-like molecules

21 January 2018

1 reference

Fetal growth and insulin secretion in adult life.

21 January 2018

1 reference

Birthweight and adult health outcomes in a biethnic population in the USA.

21 January 2018

1 reference

The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension, non-insulin-dependent diabetes, and end-stage renal disease

21 January 2018

1 reference

In vitro studies on the action of CS-045, a new antidiabetic agent

21 January 2018

1 reference

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats

21 January 2018

1 reference

Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts

21 January 2018

1 reference

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

21 January 2018

1 reference

Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells

21 January 2018

1 reference

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

21 January 2018

1 reference

Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats

21 January 2018

1 reference

Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.

21 January 2018

1 reference

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

21 January 2018

1 reference

Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.

21 January 2018

1 reference

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

21 January 2018

1 reference

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

21 January 2018

1 reference

Nonketotic diabetes mellitus: insulin deficiency or insulin resistance?

21 January 2018

1 reference

Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

21 January 2018

1 reference

Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects

21 January 2018

1 reference

Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus

21 January 2018

1 reference

Section Review: Oncologic, Endocrine & Metabolic: Thiazolidinediones

21 January 2018

1 reference

Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.17046

1 reference

8 October 2017

1 reference